BACKGROUND: The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease. METHODS: Patients with upper abdominal pain suggesting pancreatic disease (persistent over hours, pain aggravated by ingestion of food, epigastric pain radiating to the back), without a history of alcohol consumption and who exhibited no abnormalities regarding serum amylase and lipase, ultrasonography, CT and upper gastrointestinal endoscopy, were prescribed 200 mg camostat mesilate three times daily for 2 weeks. The patients were subjected to endoscopic ultrasonography (EUS) while under treatment and were distributed into those who had 4 or more suggestive findings of chronic pancreatitis (suspected pancreatic disease group), 2 or 3 (equivalent group) and those with 1 or no findings (control group). Symptom severity was recorded before and after treatment using a 10-cm visual analog scale (VAS). RESULTS: Among 95 patients, 40 were in the suspected pancreatic disease group, 30 were in the equivalent group and 25 served as controls. A significant intra- and intergroup improvement of symptoms was observed not only in the suspected pancreatic disease group but also in the equivalent group. CONCLUSIONS: Camostat mesilate may serve as a therapeutic agent for patients with dyspepsia associated with mild pancreatic disease, who do not habitually drink alcohol.
BACKGROUND: The aim of the present study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against dyspepsia associated with non-alcoholic mild pancreatic disease. METHODS:Patients with upper abdominal pain suggesting pancreatic disease (persistent over hours, pain aggravated by ingestion of food, epigastric pain radiating to the back), without a history of alcohol consumption and who exhibited no abnormalities regarding serum amylase and lipase, ultrasonography, CT and upper gastrointestinal endoscopy, were prescribed 200 mg camostat mesilate three times daily for 2 weeks. The patients were subjected to endoscopic ultrasonography (EUS) while under treatment and were distributed into those who had 4 or more suggestive findings of chronic pancreatitis (suspected pancreatic disease group), 2 or 3 (equivalent group) and those with 1 or no findings (control group). Symptom severity was recorded before and after treatment using a 10-cm visual analog scale (VAS). RESULTS: Among 95 patients, 40 were in the suspected pancreatic disease group, 30 were in the equivalent group and 25 served as controls. A significant intra- and intergroup improvement of symptoms was observed not only in the suspected pancreatic disease group but also in the equivalent group. CONCLUSIONS:Camostat mesilate may serve as a therapeutic agent for patients with dyspepsia associated with mild pancreatic disease, who do not habitually drink alcohol.
Authors: Marc F Catalano; Anand Sahai; Michael Levy; Joseph Romagnuolo; Maurits Wiersema; William Brugge; Martin Freeman; Kenji Yamao; Marcia Canto; Lyndon V Hernandez Journal: Gastrointest Endosc Date: 2009-02-24 Impact factor: 9.427
Authors: John DeWitt; Kathleen McGreevy; Julia LeBlanc; Lee McHenry; Oscar Cummings; Stuart Sherman Journal: Gastrointest Endosc Date: 2005-07 Impact factor: 9.427
Authors: A V Sahai; M Zimmerman; L Aabakken; P R Tarnasky; J T Cunningham; A van Velse; R H Hawes; B J Hoffman Journal: Gastrointest Endosc Date: 1998-07 Impact factor: 9.427
Authors: Yanchen Zhou; Punitha Vedantham; Kai Lu; Juliet Agudelo; Ricardo Carrion; Jerritt W Nunneley; Dale Barnard; Stefan Pöhlmann; James H McKerrow; Adam R Renslo; Graham Simmons Journal: Antiviral Res Date: 2015-02-07 Impact factor: 5.970
Authors: Sarah S Cherian; Megha Agrawal; Atanu Basu; Priya Abraham; Raman R Gangakhedkar; Balram Bhargava Journal: Indian J Med Res Date: 2020 Feb & Mar Impact factor: 2.375
Authors: Alimuddin Zumla; Jasper F W Chan; Esam I Azhar; David S C Hui; Kwok-Yung Yuen Journal: Nat Rev Drug Discov Date: 2016-02-12 Impact factor: 84.694